Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression. Magdaleno F, Trebicka J, et al. Department of Internal Medicine I, University of Bonn, Bonn, Germany. Gut. Feb 2017. Pubmed